Page 4 - Olatec Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Phase III and is being developed by Kringle Pharma.  HGF was given an orphan drug designation for Acute Spinal Cord Injury by the Japanese Ministry of Health, Labour and Welfare in September 2019. In October 2019, GTX Medical and NeuroRecovery Technologies announced their merger to create a leading global company committed to developing novel neuromodulation therapies to improve people’s functional recovery with Spinal Cord Injuries. The merged entity will be known as GTX Medical BV. The merged company is developing Targeted Epidural Spine Stimulation (TESS), an implantable spinal cor...

Heart failure, gout, COVID-19, melanoma Completed Phase 1 and Phase 1b in patients with heart failure and Phase 2a in patients with acute gout flares. A Phase 2 trial for people with moderate COVID-19 symptoms is ongoing, and the company is planning a Phase 2 trial in late-stage melanoma, along with an approved immunotherapy. Drugging the inflammasome For years after the inflammasome’s initial discovery, the search for drugs that target it yielded no promising leads, Cooper says. “Big pharma all went and screened their libraries of drugs and said, can we find an inhibitor? But no one cou...

This Viewpoint summarizes the pathophysiology and clinical features of atherosclerotic plaque erosion as an underlying mechanism of acute coronary syndromes (AC

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience News provided by Share this article Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer NEW YORK, Jan. 14, 2021 /PRNewswire/ -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Officer. Mr. Barrow has over a decade of experience leading drug development programs aimed at identifying...

Published: Dec 29, 2020   The data are published in the Proceedings of the National Academy of Sciences Results suggest a potential therapeutic benefit for dapansutrile in patients with neuroinflammatory diseases, e.g., Alzheimer’s Disease Preclinical results encourage clinical research with dapansutrile in Alzheimer’s Disease to investigate therapeutic effect in humans   NEW YORK--(BUSINESS WIRE)-- Olatec Therapeutics LLC (“Olatec”) today announced the publication of data demonstrating the benefits of its selective NLRP3 inhibitor, dapansutrile, in a mouse model of Alzheimer�...